No­var­tis has scrapped a fifth of its pro­grams in pur­suit of 'tru­ly im­pact­ful' drugs, Brad­ner re­veals

It turns out the wave of glob­al re­struc­tur­ing at No­var­tis has claimed more than just jobs — it’s al­so tak­en a siz­able chunk of its re­search pipeline.

In an in­ter­view with Bloomberg, Jay Brad­ner, pres­i­dent of the No­var­tis In­sti­tutes for Bio­med­ical Re­search, re­vealed that the phar­ma gi­ant has scrapped 90 drug pro­grams af­ter a re­view, down­siz­ing its port­fo­lio from 430 to 340.

The fate of these as­sets might range from di­vesti­ture to ter­mi­na­tion to sit­ting “on the shelf for a lit­tle while,” he added, giv­ing way to the “tru­ly im­pact­ful, tru­ly dif­fer­en­ti­at­ed, tru­ly im­por­tant med­i­cines” his team will now fo­cus on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER